{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:53:21Z","timestamp":1792511601981,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04434-1","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T07:59:16Z","timestamp":1758355156000},"page":"1472-1478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety of Romosozumab in women with cancer and osteoporosis at high risk of fractures"],"prefix":"10.1007","volume":"90","author":[{"given":"Roberto","family":"Colle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Piasentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrezia","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bodini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Jaafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Francesca","family":"Birtolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bertoldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gherardo","family":"Mazziotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea G.","family":"Lania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,20]]},"reference":[{"issue":"11","key":"4434_CR1","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1007\/s40618-024-02395-2","volume":"47","author":"L Cianferotti","year":"2024","unstructured":"L. Cianferotti, C. Cipriani, A. Palermo, O. Viapiana, G. Zavatta, G. Mazziotti, A practical approach for anabolic treatment of bone fragility with Romosozumab. J. Endocrinol. Invest. 47(11), 2649\u20132662 (2024). https:\/\/doi.org\/10.1007\/s40618-024-02395-2","journal-title":"J. Endocrinol. Invest."},{"key":"4434_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bone.2016.11.013","volume":"96","author":"MM Weivoda","year":"2017","unstructured":"M.M. Weivoda, S.J. Youssef, M.J. Oursler, Sclerostin expression and functions beyond the osteocyte. Bone. 96, 45\u201350 (2017). https:\/\/doi.org\/10.1016\/j.bone.2016.11.013","journal-title":"Bone"},{"issue":"16","key":"4434_CR3","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"F. Cosman, D.B. Crittenden, J.D. Adachi, N. Binkley, E. Czerwinski, S. Ferrari et al., Romosozumab treatment in postmenopausal women with osteoporosis. N Engl. J. Med. 375(16), 1532\u20131543 (2016). https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"N Engl. J. Med."},{"issue":"5","key":"4434_CR4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"M.R. McClung, A. Grauer, S. Boonen, M.A. Bolognese, J.P. Brown, A. Diez-Perez et al., Romosozumab in postmenopausal women with low bone mineral density. N Engl. J. Med. 370(5), 412\u2013420 (2014). https:\/\/doi.org\/10.1056\/NEJMoa1305224","journal-title":"N Engl. J. Med."},{"issue":"2","key":"4434_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ceb.2007.02.007","volume":"19","author":"R Fodde","year":"2007","unstructured":"R. Fodde, T. Brabletz, Wnt\/beta-catenin signaling in cancer stemness and malignant behavior. Curr. Opin. Cell. Biol. 19(2), 150\u2013158 (2007). https:\/\/doi.org\/10.1016\/j.ceb.2007.02.007","journal-title":"Curr. Opin. Cell. Biol."},{"issue":"11","key":"4434_CR6","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/onc.2016.304","volume":"36","author":"T Zhan","year":"2017","unstructured":"T. Zhan, N. Rindtorff, M. Boutros, Wnt signaling in cancer. Oncogene. 36(11), 1461\u20131473 (2017). https:\/\/doi.org\/10.1038\/onc.2016.304","journal-title":"Oncogene"},{"issue":"1","key":"4434_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc3419","volume":"13","author":"JN Anastas","year":"2013","unstructured":"J.N. Anastas, R.T. Moon, WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer. 13(1), 11\u201326 (2013). https:\/\/doi.org\/10.1038\/nrc3419","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"4434_CR8","doi-asserted-by":"publisher","first-page":"a008052","DOI":"10.1101\/cshperspect.a008052","volume":"4","author":"P Polakis","year":"2012","unstructured":"P. Polakis, Wnt signaling in cancer. Cold Spring Harb Perspect. Biol. 4(5), a008052 (2012). https:\/\/doi.org\/10.1101\/cshperspect.a008052","journal-title":"Cold Spring Harb Perspect. Biol."},{"issue":"6","key":"4434_CR9","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.cell.2012.05.012","volume":"149","author":"H Clevers","year":"2012","unstructured":"H. Clevers, R. Nusse, Wnt\/\u03b2-catenin signaling and disease. Cell. 149(6), 1192\u20131205 (2012). https:\/\/doi.org\/10.1016\/j.cell.2012.05.012","journal-title":"Cell"},{"issue":"12","key":"4434_CR10","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nrm3470","volume":"13","author":"C Niehrs","year":"2012","unstructured":"C. Niehrs, The complex world of WNT receptor signalling. Nat. Rev. Mol. Cell. Biol. 13(12), 767\u2013779 (2012). https:\/\/doi.org\/10.1038\/nrm3470","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"6","key":"4434_CR11","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.2353\/ajpath.2010.091125","volume":"176","author":"AI Khramtsov","year":"2010","unstructured":"A.I. Khramtsov, G.F. Khramtsova, M. Tretiakova, D. Huo, O.I. Olopade, K.H. Goss, Wnt\/\u03b2-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am. J. Pathol. 176(6), 2911\u20132920 (2010). https:\/\/doi.org\/10.2353\/ajpath.2010.091125","journal-title":"Am. J. Pathol."},{"issue":"3","key":"4434_CR12","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/1078-0432.CCR-10-1791","volume":"17","author":"FC Geyer","year":"2011","unstructured":"F.C. Geyer, M. Lacroix-Triki, K. Savage, M. Arnedos, M.B. Lambros, A. MacKay et al., \u03b2-Catenin pathway activation in breast cancer: implications for pathogenesis and treatment. Clin. Cancer Res. 17(3), 752\u2013759 (2011). https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1791","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"4434_CR13","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.3892\/ijo.26.6.1613","volume":"26","author":"M Katoh","year":"2005","unstructured":"M. Katoh, WNT signaling in gastric cancer (review). Int. J. Oncol. 26(6), 1613\u20131620 (2005). https:\/\/doi.org\/10.3892\/ijo.26.6.1613","journal-title":"Int. J. Oncol."},{"issue":"4","key":"4434_CR14","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/ng1336","volume":"36","author":"H Suzuki","year":"2004","unstructured":"H. Suzuki, D.N. Watkins, K.W. Jair, K.E. Schuebel, S.D. Markowitz, W.D. Chen et al., Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet. 36(4), 417\u2013422 (2004). https:\/\/doi.org\/10.1038\/ng1336","journal-title":"Nat. Genet."},{"issue":"6","key":"4434_CR15","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nrneurol.2012.61","volume":"8","author":"PA Northcott","year":"2012","unstructured":"P.A. Northcott, A. Korshunov, S.M. Pfister, M.D. Taylor, The clinical implications of Medulloblastoma subgroups. Nat. Rev. Neurol. 8(6), 340\u2013351 (2012). https:\/\/doi.org\/10.1038\/nrneurol.2012.61","journal-title":"Nat. Rev. Neurol."},{"issue":"8","key":"4434_CR16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nri2360","volume":"8","author":"FJ Staal","year":"2008","unstructured":"F.J. Staal, T.C. Luis, M.M. Tiemessen, WNT signalling in the immune system: WNT is spreading its wings. Nat. Rev. Immunol. 8(8), 581\u2013593 (2008). https:\/\/doi.org\/10.1038\/nri2360","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"4434_CR17","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","volume":"12","author":"C Zhao","year":"2007","unstructured":"C. Zhao, J. Blum, A. Chen, H.Y. Kwon, S.H. Jung, J.M. Cook et al., Loss of \u03b2-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell. 12(6), 528\u2013541 (2007). https:\/\/doi.org\/10.1016\/j.ccr.2007.11.003","journal-title":"Cancer Cell."},{"key":"4434_CR18","doi-asserted-by":"publisher","first-page":"115361","DOI":"10.1016\/j.bone.2020.115361","volume":"136","author":"T Sato","year":"2020","unstructured":"T. Sato, N. Takahashi, I. Takada, Safety and potential risks of anti-sclerostin therapy in osteoporosis: a review. Bone. 136, 115361 (2020). https:\/\/doi.org\/10.1016\/j.bone.2020.115361","journal-title":"Bone"},{"issue":"9596","key":"4434_CR19","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von E. Elm, D.G. Altman, M. Egger, S.J. Pocock, P.C. G\u00f8tzsche, J.P. Vandenbroucke, STROBE Initiative, The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 370(9596), 1453\u20131457 (2007). https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X","journal-title":"Lancet"},{"issue":"11","key":"4434_CR20","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1007\/s40618-023-02082-8","volume":"46","author":"G Adami","year":"2023","unstructured":"G. Adami, A. Biffi, G. Porcu, R. Ronco, R. Alvaro, R. Bogini, A.P. Caputi, L. Cianferotti, B. Frediani, D. Gatti, S. Gonnelli, G. Iolascon, A. Lenzi, S. Leone, S. Migliaccio, T. Nicoletti, M. Paoletta, A. Pennini, E. Piccirilli, U. Tarantino, M.L. Brandi, G. Corrao, M. Rossini, R. Michieli, A systematic review on the performance of fracture risk assessment tools: FRAX, DeFRA, FRA-HS. J. Endocrinol. Invest. 46(11), 2287\u20132297 (2023). https:\/\/doi.org\/10.1007\/s40618-023-02082-8","journal-title":"J. Endocrinol. Invest."},{"key":"4434_CR21","unstructured":"https:\/\/www.iss.it\/documents\/20126\/8403839\/LG_C0013_AIOM_Ca-mammario-precoce.pdf\/fb5df1bd-2712-9166-68e7-6e296912776e?t=1704702928747"},{"key":"4434_CR22","unstructured":"https:\/\/www.iss.it\/documents\/20126\/8403839\/LG_C008_AIOM_Ca-mammario-avanzato-TTT2.pdf"},{"key":"4434_CR23","unstructured":"https:\/\/www.iss.it\/documents\/20126\/8403839\/LG+486+AIOM_Ca+Cervice-Endometrio_agg2025.pdf\/94f157e0-4ea0-3bdd-4aaf-f9e372b21215?t=1748440598835"},{"key":"4434_CR24","unstructured":"https:\/\/www.iss.it\/documents\/20126\/8403839\/LG+279+Retto+e+Ano_agg2025.pdf\/6b78cb84-7e6b-2fef-ce77-2dad8f64760b?t=1742888997568"},{"key":"4434_CR25","unstructured":"https:\/\/www.iss.it\/documents\/20126\/8403839\/LG+127_Melanoma_agg-ago2023_rev-nov.pdf\/d1e6e188-6e08-8cd6-5ac7-3e1f83dce7c6?t=1702303171666"},{"key":"4434_CR26","unstructured":"https:\/\/www.iss.it\/documents\/20126\/8403839\/LG%20502%20AIOM_Ca%20ovaio%202021"},{"key":"4434_CR27","unstructured":"https:\/\/www.aiom.it\/wp-content\/uploads\/2018\/11\/2018_LG_AIOM_Linfomi.pdf"},{"key":"4434_CR28","unstructured":"http:\/\/media.aiom.it\/userfiles\/files\/doc\/LG\/2017_LGAIOM_Mieloma.pdf"},{"key":"4434_CR29","doi-asserted-by":"publisher","first-page":"1759720X1986385","DOI":"10.1177\/1759720X19863853","volume":"11","author":"EM Lewiecki","year":"2019","unstructured":"E.M. Lewiecki, Romosozumab: clinical utility and patient selection in the management of osteoporosis. Ther. Adv. Musculoskelet. Dis. 11, 1759720X19863853 (2019). https:\/\/doi.org\/10.1177\/1759720X19863853","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"issue":"12","key":"4434_CR30","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1002\/jbmr.510","volume":"26","author":"D Padhi","year":"2011","unstructured":"D. Padhi, M. Allison, A.J. Kivitz, M.J. Gutierrez, B. Stouch, C. Wang et al., Multiple-dose, randomized, placebo-controlled study of AMG 785, a sclerostin monoclonal antibody. J. Bone Min. Res. 26(12), 2734\u20132742 (2011). https:\/\/doi.org\/10.1002\/jbmr.510","journal-title":"J. Bone Min. Res."},{"issue":"Suppl 3","key":"4434_CR31","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.2215\/CJN.04151206","volume":"3","author":"B Clarke","year":"2008","unstructured":"B. Clarke, Normal bone anatomy and physiology. Clin. J. Am. Soc. Nephrol. 3(Suppl 3), S131\u2013S139 (2008). https:\/\/doi.org\/10.2215\/CJN.04151206","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"11","key":"4434_CR32","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/S2213-8587(17)30188-2","volume":"5","author":"S Khosla","year":"2017","unstructured":"S. Khosla, L.C. Hofbauer, Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 5(11), 898\u2013907 (2017). https:\/\/doi.org\/10.1016\/S2213-8587(17)30188-2","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"4434_CR33","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1097\/CCO.0b013e3282f08d5f","volume":"19","author":"N Giuliani","year":"2007","unstructured":"N. Giuliani, S. Colla, V. Rizzoli, New insight in the pathogenesis of myeloma bone disease. Curr. Opin. Oncol. 19(6), 650\u2013655 (2007). https:\/\/doi.org\/10.1097\/CCO.0b013e3282f08d5f","journal-title":"Curr. Opin. Oncol."},{"issue":"6","key":"4434_CR34","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/ijc.27342","volume":"131","author":"E Terpos","year":"2012","unstructured":"E. Terpos, D. Christoulas, E. Katodritou, C. Bratengeier, M. Gkotzamanidou, E. Michalis et al., Elevated Circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy. Int. J. Cancer. 131(6), 1466\u20131471 (2012). https:\/\/doi.org\/10.1002\/ijc.27342","journal-title":"Int. J. Cancer"},{"issue":"12","key":"4434_CR35","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1038\/leu.2017.152","volume":"31","author":"J Delgado-Calle","year":"2017","unstructured":"J. Delgado-Calle, J. Anderson, M.D. Cregor, K.W. Condon, S.A. Kuhstoss, L.I. Plotkin et al., Genetic deletion of Sost or Pharmacological Inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth. Leukemia. 31(12), 2686\u20132694 (2017). https:\/\/doi.org\/10.1038\/leu.2017.152","journal-title":"Leukemia"},{"issue":"2","key":"4434_CR36","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1152\/physrev.00013.2019","volume":"100","author":"J Delgado-Calle","year":"2020","unstructured":"J. Delgado-Calle, T. Bellido, The osteocyte as a signaling cell. Physiol. Rev. 100(2), 1143\u20131169 (2020). https:\/\/doi.org\/10.1152\/physrev.00013.2019","journal-title":"Physiol. Rev."},{"issue":"22","key":"4434_CR37","doi-asserted-by":"publisher","first-page":"35103","DOI":"10.18632\/oncotarget.9155","volume":"7","author":"R Silbermann","year":"2016","unstructured":"R. Silbermann, M. Bolzoni, P. Storti, D. Guasco, S. Bonomini, D. Zhou et al., Bone marrow mononuclear cells from multiple myeloma patients induce osteocyte apoptosis. Oncotarget. 7(22), 35103\u201335117 (2016). https:\/\/doi.org\/10.18632\/oncotarget.9155","journal-title":"Oncotarget"},{"issue":"26","key":"4434_CR38","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1182\/blood-2016-10-747931","volume":"129","author":"MM McDonald","year":"2017","unstructured":"M.M. McDonald, M.R. Reagan, S.E. Youlten, S.T. Mohanty, A. Seckinger, R.L. Terry et al., Inhibiting the osteocyte-specific protein sclerostin increases bone mass and impairs bone metastasis in multiple myeloma. Blood. 129(26), 3469\u20133479 (2017). https:\/\/doi.org\/10.1182\/blood-2016-10-747931","journal-title":"Blood"},{"issue":"1","key":"4434_CR39","doi-asserted-by":"publisher","first-page":"11399","DOI":"10.1038\/s41598-017-11913-7","volume":"7","author":"M Zhu","year":"2017","unstructured":"M. Zhu, C. Liu, S. Li, S. Zhang, Q. Yao, Q. Song, Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer. Sci. Rep. 7(1), 11399 (2017). https:\/\/doi.org\/10.1038\/s41598-017-11913-7","journal-title":"Sci. Rep."},{"issue":"9","key":"4434_CR40","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.3390\/cancers15092645","volume":"15","author":"A Anloague","year":"2023","unstructured":"A. Anloague, J. Delgado-Calle, Osteocytes, New kids on the block for cancer in bone therapy. Cancers (Basel). 15(9), 2645 (2023). https:\/\/doi.org\/10.3390\/cancers15092645","journal-title":"Cancers (Basel)"},{"key":"4434_CR41","doi-asserted-by":"publisher","first-page":"105773","DOI":"10.1016\/j.jsbmb.2020.105773","volume":"204","author":"RI El-Mahdy","year":"2020","unstructured":"R.I. El-Mahdy, M.M. Zakhary, D.W. Maximous, A.A. Mokhtar, El M.I. Dosoky, Circulating osteocyte-related biomarkers (vitamin D, sclerostin, dickkopf-1), hepcidin, and oxidative stress markers in early breast cancer: their impact in disease progression and outcome. J. Steroid Biochem. Mol. Biol. 204, 105773 (2020). https:\/\/doi.org\/10.1016\/j.jsbmb.2020.105773","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"4434_CR42","doi-asserted-by":"publisher","first-page":"115926","DOI":"10.1016\/j.bone.2021.115926","volume":"146","author":"IR Reid","year":"2021","unstructured":"I.R. Reid, A.M. Horne, B. Mihov, E. Garratt, J. Yang, A. Grey, Effect of Romosozumab on bone mineral density in women with postmenopausal osteoporosis and mild-to-moderate chronic kidney disease. Bone. 146, 115926 (2021). https:\/\/doi.org\/10.1016\/j.bone.2021.115926","journal-title":"Bone"},{"issue":"7","key":"4434_CR43","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.3390\/medicina59071316","volume":"59","author":"Y Zhou","year":"2023","unstructured":"Y. Zhou et al., Radiation induces bone microenvironment disruption by activating the STING-TBK1 pathway. Medicina. 59(7), 1316 (2023). https:\/\/doi.org\/10.3390\/medicina59071316","journal-title":"Medicina"},{"issue":"15","key":"4434_CR44","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"K.G. Saag, J. Petersen, M.L. Brandi et al., Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl. J. Med. 377(15), 1417\u20131427 (2017). https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl. J. Med."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04434-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04434-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04434-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T18:03:36Z","timestamp":1765908216000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04434-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,20]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4434"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04434-1","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,20]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"G. Mazziotti was consultant for Sanofi and Sandoz, and received lecture fees from UCB and Theramex. F. Bertoldo has been consultant or speaker for Abiogen, Amgen, UCB pharma, Chiesi and SPA. The other Authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of IRCCS Humanitas Research Hospital\n                      ,\n                      Rozzano-Milan\n                      ,\n                      Italy (26\/06\/2023; No 3138).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}